Protein therapeutics have delivered tremendous value to patients, but have many limitations that cannot be corrected utilizing the natural amino acids. With Synthorx’s Expanded Genetic Alphabet platform technology, we can design and scale-up novel proteins with improved pharmacological properties, with the goal of making more efficacious, safer, and convenient therapeutics for patients.
synthorx.com was registered 1 decade 8 months ago. It is a domain having .com extension. It is estimated worth of $ 8.95 and have a daily income of around $ 0.15. As no active threats were reported recently, synthorx.com is SAFE to browse.
Daily Unique Visitors: | Not Applicable |
Daily Pageviews: | Not Applicable |
Income Per Day: | $ 0.15 |
Estimated Worth: | $ 8.95 |
Google Indexed Pages: | Not Applicable |
Yahoo Indexed Pages: | Not Applicable |
Bing Indexed Pages: | Not Applicable |
Google Backlinks: | Not Applicable |
Bing Backlinks: | Not Applicable |
Alexa BackLinks: | Not Applicable |
Google Safe Browsing: | No Risk Issues |
Siteadvisor Rating: | Not Applicable |
WOT Trustworthiness: | Very Poor |
WOT Privacy: | Very Poor |
WOT Child Safety: | Very Poor |
Alexa Rank: | Not Applicable |
PageSpeed Score: | Not Applicable |
Domain Authority: | 49 ON 100 |
Bounce Rate: | Not Applicable |
Time On Site: | Not Applicable |
Total Traffic: | No Data |
Direct Traffic: | No Data |
Referral Traffic: | No Data |
Search Traffic: | No Data |
Social Traffic: | No Data |
Mail Traffic: | No Data |
Display Traffic: | No Data |
The Synthorx team. At Synthorx, we focus on making significant advancements in protein design to deliver optimized therapeutics – called Synthorins – to improve the lives of...
Synthorx. 450 likes. We're using our first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune...
Real time Synthorx (THOR) stock price quote, stock graph, news & analysis.
Synthorx, Inc. is a biopharmaceutical company. The Company is focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders.
Dec 09, 2019 · Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion. Proprietary immuno-oncology (IO) platform synergistic with Sanofi’s existing...
Dec 09, 2019 · Sanofi to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 Billion. Proprietary immuno-oncology (IO) platform synergistic with …
Synthorx, Inc. is a biotechnology company focused on prolonging and improving the lives of people with cancer and autoimmune disorders. Synthorx’s proprietary, first-of-its-kind...
Synthorx. 455 likes. We're using our first-of-its-kind Expanded Genetic Alphabet platform technology to discover and develop optimized biologics for cancer and autoimmune...
01/23: SYNTHORX, INC.: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing,...
Dec 10, 2019 · The Synthorx deal isn't anywhere near the size of the Genzyme one, but it doesn't have to be. It is the right element at the right time to boost businesses that...
Dec 10, 2019 · Synthorx’s lead drug candidate is THOR-707, an IL-2 therapeutic that it has in development both as a single agent and in combination with …
Dec 09, 2019 · The drug at the center of this new deal is Synthorx’s investigational medicine code-named THOR-707. Meant to treat solid tumors, the drug is …
Dec 30, 2019 · Synthorx picked Sanofi out of a field of four suitors for IL-2 candidate THOR-707, ultimately nailing down a 172% premium on the biotech's Dec. 5 …
Which of the following are the two new nucleotides that have been created by the company Synthorx? a. Z b. H c. X d. Y. c. X d. Y. Why did early molecular geneticists know that...
Dec 09, 2019 · Sanofi has struck a deal to buy Synthorx for $2.5 billion (€2.3 billion). The takeover, the first of Paul Hudson’s time as CEO, will give Sanofi control of an...
H1 Headings: | 2 | H2 Headings: | 28 |
H3 Headings: | Not Applicable | H4 Headings: | Not Applicable |
H5 Headings: | Not Applicable | H6 Headings: | Not Applicable |
Total IFRAMEs: | Not Applicable | Total Images: | 10 |
Google Adsense: | Not Applicable | Google Analytics: | UA-118225458-1 |
Words | Occurrences | Density | Possible Spam |
---|---|---|---|
in vitro | 4 | 0.685 % | No |
the first | 4 | 0.685 % | No |
publishes first | 3 | 0.514 % | No |
we are | 3 | 0.514 % | No |
vitro translation | 3 | 0.514 % | No |
2018 Synthorx | 3 | 0.514 % | No |
Romesberg lab | 3 | 0.514 % | No |
genetic information | 3 | 0.514 % | No |
to improve | 3 | 0.514 % | No |
CA 92037 | 2 | 0.342 % | No |
PCR amplified | 2 | 0.342 % | No |
La Jolla | 2 | 0.342 % | No |
publish the | 2 | 0.342 % | No |
Torrey Pines | 2 | 0.342 % | No |
first UBP | 2 | 0.342 % | No |
2019 Synthorx | 2 | 0.342 % | No |
of people | 2 | 0.342 % | No |
Privacy Policy | 2 | 0.342 % | No |
publishes on | 2 | 0.342 % | No |
on the | 2 | 0.342 % | No |
Words | Occurrences | Density | Possible Spam |
---|---|---|---|
medicine is in oursynthetic | 2 | 0.342 % | No |
is in oursynthetic DNA | 2 | 0.342 % | No |
La Jolla CA 92037 | 2 | 0.342 % | No |
Better medicine is in | 2 | 0.342 % | No |
Application for THOR707 paving | 1 | 0.171 % | No |
for THOR707 paving the | 1 | 0.171 % | No |
THOR707 paving the way | 1 | 0.171 % | No |
IND Application for THOR707 | 1 | 0.171 % | No |
the IND Application for | 1 | 0.171 % | No |
from FDA for the | 1 | 0.171 % | No |
FDA for the IND | 1 | 0.171 % | No |
for the IND Application | 1 | 0.171 % | No |
paving the way for | 1 | 0.171 % | No |
the US Protein therapeutics | 1 | 0.171 % | No |
for enrollment to proceed | 1 | 0.171 % | No |
enrollment to proceed in | 1 | 0.171 % | No |
to proceed in the | 1 | 0.171 % | No |
way for enrollment to | 1 | 0.171 % | No |
the way for enrollment | 1 | 0.171 % | No |
in the US Protein | 1 | 0.171 % | No |
Infutor's consumer data, intelligence, and identity resolution solutions help improve acquisition, increase omnichannel reach, and drive conversions.
Working to protect the people of Florida from the dangers of tobacco and smoking. Discover how to quit with the help of Tobacco Free Florida.
Cyara is the world’s leading Automated Customer Experience Assurance Platform provider, helping leading brands deliver better CX with less effort, cost, time, and risk. Cyara...
SlutBox is a monthly subscription by Amber Rose focused on beauty, fashion, body positivity and activism. Join MySlutBox.com to get yours!
Cloud-based transportation management system (TMS) provides freight intelligence & meets the requirements of every supply chain. Try Kuebix Software Now!
Domain Registrar: | Register.com, Inc. |
---|---|
Registration Date: | 2014-02-26 1 decade 8 months 3 weeks ago |
Last Modified: | 2019-01-31 5 years 9 months 2 weeks ago |
Host | Type | TTL | Extra |
---|---|---|---|
synthorx.com | A | 14359 |
IP: 35.190.184.136 |
synthorx.com | NS | 14400 |
Target: dns014.b.register.com |
synthorx.com | NS | 14400 |
Target: dns010.d.register.com |
synthorx.com | NS | 14400 |
Target: dns142.c.register.com |
synthorx.com | NS | 14400 |
Target: dns022.a.register.com |
synthorx.com | SOA | 14400 |
MNAME: dns022.a.register.com RNAME: root.register.com Serial: 2014022517 Refresh: 28800 Retry: 7200 Expire: 604800 |
synthorx.com | MX | 14400 |
Target: synthorx-com.mail.protection.outlook.com |
synthorx.com | TXT | 14400 |
TXT: v=spf1 include:spf.protection.outlook.com -all |
Get more done with the new Google Chrome. A more simple, secure, and faster web browser than ever, with Google’s smarts built-in. Download now.
Log into Facebook to start sharing and connecting with your friends, family, and people you know.
腾讯网从2003年创立至今,已经成为集新闻信息,区域垂直生活服务、社会化媒体资讯和产品为一体的互联网媒体平台。腾讯网下设新闻、科技、财经、娱乐、体育、汽车、时尚等多个频道,充分满足用户对不同类型资讯的需求。同时专注不同领域内容,打造精品栏目,并顺应技术发展趋势,推出网络直播等创新形式,改变了用户获取资讯的方式和习惯。
Free shipping on millions of items. Get the best of Shopping and Entertainment with Prime. Enjoy low prices and great deals on the largest selection of everyday essentials and...